NCT03231293已完成不适用
A Multicenter Longitudinal Observational Study to Assess the Effectiveness of Fimasartan-based Antihypertensive Treatment and Prognosis in Post-Acute Phase of Ischemic Stroke or Transient Ischemic Attack
适应症
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 入组人数
- 1,035
- 试验地点
- 27
- 主要终点
- BP
研究概览
简要总结
This study evaluates the effectiveness of fimasartan-based antihypertensive treatment and prognosis in post-acute phase of ischemic stroke or transient ischemic attack patients. All participants will receive fimasartan, and the investigators will follow them up for 6 months.
研究设计
- 研究类型
- Observational
- 观察模型
- Case Only
- 时间视角
- Prospective
入排标准
- 年龄范围
- 19 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Ischemic stroke or transient ischemic attack occurs after 7 days to 3 months.
- •Mean blood pressure measured 3 times at the first visit (Visit 1) should be over 140 mmHg for systolic blood pressure or 90 mmHg for diastolic blood pressure
- •Suitable for administration of fimasartan
- •The life expectancy should be over 6 months.
排除标准
- •Patients already treated with antihypertensive medications
- •Hemorrhagic stroke patients
结局指标
主要结局
BP
时间窗: 24 weeks
Blood pressure control rate(\<140/90 mmHg)
次要结局
- Adverse events(24 weeks)
- mRS(4, 12, 24 weeks)
- Cardiovascular events(24 weeks)
- Mortality rates from cardiovascular disease(24 weeks)
- Stroke recurrence(24 weeks)
- BP(4, 12, 24 weeks)
- Fimasartan-based treatment(24 weeks)
- Fimasartan starting point(24 weeks)
- Mortality rates of any cause(24 weeks)
研究者
研究点 (27)
Loading locations...
相似试验
已完成
3 期
A Clinical Study to Evaluate Efficacy and Safety of Fimasartan/Hydrochlorothiazide Combination-therapyEssential HypertensionNCT01258673Boryung Pharmaceutical Co., Ltd263
已完成
3 期
Clinical Study to Evaluate the Antihypertensive Efficacy and Safety of Fimasartan in Hypertension PatientsHypertensionNCT00922480Boryung Pharmaceutical Co., Ltd506
已完成
2 期
A Therapeutic Exploratory Clinical Study to Evaluate the Antihypertensive Efficacy of Fimasartan (BR-A-657•K) During 24 Hours in Patients With Mild to Moderate Essential HypertensionEssential HypertensionNCT00922441Boryung Pharmaceutical Co., Ltd92
已完成
2 期
A Randomized, Double-Blind, Placebo-Controlled, 3x3 Factorial Design, Phase II Study to Evaluate the Antihypertensive Efficacy and Safety of Combination of Fimasartan and Amlodipine in Patients With Essential HypertensionHypertensionNCT01518998Boryung Pharmaceutical Co., Ltd420
已完成
不适用
Therapy of Essential Hypertension With Kinzal®/ Kinzalplus®HypertensionNCT00927537Bayer2,052